Charles Schwab
ATOS icon

Charles Schwab’s Atossa Therapeutics ATOS Stock Holding History

Charles Schwab’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,333
Closed -$47.2K – 3461
2025
Q4 		$47.2K Hold
5,333
– – ﹤0.01% 3428
2025
Q3 		$69.4K Hold
5,333
– – ﹤0.01% 3407
2025
Q2 		$66.4K Sell
5,333
-22,839
-81% -$273K ﹤0.01% 3435
2025
Q1 		$284K Buy
28,172
+8,062
+40% +$97.9K ﹤0.01% 3218
2024
Q4 		$285K Sell
20,110
-3,064
-13% -$59.8K ﹤0.01% 3277
2024
Q3 		$528K Sell
23,174
-1,492
-6% -$30.1K ﹤0.01% 3137
2024
Q2 		$440K Buy
24,666
+21,602
+705% +$478K ﹤0.01% 3253
2024
Q1 		$82.7K Hold
3,064
– – ﹤0.01% 3325
2023
Q4 		$40.4K Hold
3,064
– – ﹤0.01% 3422
2023
Q3 		$33.9K Hold
3,064
– – ﹤0.01% 3448
2023
Q2 		$57.9K Hold
3,064
– – ﹤0.01% 3401
2023
Q1 		$33.3K Hold
3,064
– – ﹤0.01% 3431
2022
Q4 		$24.3K Hold
3,064
– – ﹤0.01% 3478
2022
Q3 		$39K Hold
3,064
– – ﹤0.01% 3387
2022
Q2 		$51K Sell
3,064
-17,863
-85% -$281K ﹤0.01% 3390
2022
Q1 		$393K Buy
20,927
+965
+5% +$19.6K ﹤0.01% 3151
2021
Q4 		$480K Hold
19,962
– – ﹤0.01% 3157
2021
Q3 		$977K Buy
19,962
+365
+2% +$21.2K ﹤0.01% 2880
2021
Q2 		$1.86M Buy
19,597
+17,776
+976% +$941K ﹤0.01% 2740
2021
Q1 		$58K Buy
+1,821
New +$66.5K ﹤0.01% 3426

Other funds holding ATOS

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab's ATOS Position: Q1 2026 in Review

Charles Schwab sold out of Atossa Therapeutics (ATOS) in Q1 2026, closing a stake of 5,333 shares — an estimated $47.2K sold.

Charles Schwab first reported a position in ATOS in Q1 2021 and held it in 20 quarters. The position peaked at $1.86M in Q2 2021. 33 funds tracked by Wall St. Rank hold ATOS as of Q1 2026.

  • Charles Schwab reported no remaining Atossa Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Charles Schwab sold 5,333 Atossa Therapeutics shares in Q1 2026, an estimated $47.2K.
  • Charles Schwab first reported a position in Atossa Therapeutics in Q1 2021 and held it in 20 quarters.
  • Charles Schwab's Atossa Therapeutics position peaked at $1.86M in Q2 2021.
  • 33 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q1 2026.

Based on Charles Schwab's 13F filing for Q1 2026, filed 15 May 2026.